# Laura Biganzoli

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/laura-biganzoli/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,938 |
| Field | Breast Cancer Treatment Studies |
| h-index | 66 |
| i10-index | 175 |
| OpenAlex ID | https://openalex.org/A5050421775 |
| ORCID iD | https://orcid.org/0000-0001-7989-8658 |
| Works | 470 |

## Researcher papers

- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)](https://scholariq.org/papers/4th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-4/)
- [Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study](https://scholariq.org/papers/pertuzumab-trastuzumab-and-docetaxel-for-her2-positive-metastatic-breast-cancer/)
- [Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial](https://scholariq.org/papers/pembrolizumab-plus-trastuzumab-in-trastuzumab-resistant-advanced-her2-positive/)
- [進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)](https://scholariq.org/papers/eso-esmo-abc-4/)
- [Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer](https://scholariq.org/papers/mature-results-of-a-randomized-phase-ii-multicenter-study-of-exemestane-versus/)
- [Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial](https://scholariq.org/papers/doxorubicin-and-paclitaxel-versus-doxorubicin-and-cyclophosphamide-as-first-line/)
- [6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)](https://scholariq.org/papers/6th-and-7th-international-consensus-guidelines-for-the-management-of-advanced/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.